Medicare GLP-1 Bridge Program: $50 a Month for Weight Loss Medications
For the first time, Medicare is covering GLP-1 medications for weight loss - at a flat $50 monthly copay. Here is what the Bridge program is, who can use it, which drugs qualify, why it sits outside your Part D benefit, and what happens when it ends.
Last updated: August 3, 2026
Quick Answer
The Medicare GLP-1 Bridge is a CMS demonstration program that lets eligible Medicare beneficiaries with Part D coverage get certain GLP-1 weight loss medications for a flat $50 per month. It began July 1, 2026 and is currently scheduled to run through December 31, 2027. Drugs discussed in connection with the program include Ozempic, Wegovy, and Zepbound.
The critical structural detail: GLP-1 drugs furnished under the Bridge are provided outside the Part D benefit. That means your $50 copay does not count toward your Part D deductible or out-of-pocket threshold, and the program operates separately from your normal drug plan. It is called a "bridge" for a reason - it is a time-limited demonstration, not permanent coverage.
To confirm your eligibility, contact 1-800-MEDICARE or visit Medicare.gov. Eligibility determinations are made by Medicare, not by prescribers or pharmacies, and are the single thing you should verify directly rather than from any third-party summary.
What Is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a demonstration program run by the Centers for Medicare & Medicaid Services (CMS). Under it, eligible Medicare beneficiaries with Part D coverage can obtain certain GLP-1 medications for weight management at a fixed copayment of $50 for a monthly supply.
To understand why this exists, you need one piece of history. For years, a statutory exclusion barred Medicare Part D from covering drugs used for weight loss. That exclusion dates to an era when weight loss drugs were largely regarded as cosmetic or lifestyle products. It meant that a Medicare beneficiary could get semaglutide covered as Ozempic for type 2 diabetes, but the same molecule prescribed as Wegovy for obesity was excluded.
That distinction became increasingly indefensible as evidence accumulated that obesity is a chronic disease and that GLP-1 medications reduce cardiovascular events, improve sleep apnea, and produce durable metabolic benefits. The Bridge program is CMS's mechanism for providing access without waiting for that statutory exclusion to be rewritten - which is precisely why the drugs are furnished outside the Part D benefit rather than within it.
The word "bridge" is doing real work here. This is a time-limited demonstration currently scheduled to run July 1, 2026 through December 31, 2027. It is designed to provide access during a transition period while broader coverage and pricing changes phase in. Plan around the end date rather than assuming it will automatically continue.
The Bridge is part of a wider set of federal actions on GLP-1 pricing announced for 2026, which also included reduced cash prices through direct-to-consumer channels beginning earlier in the year.
Why This Is a Genuinely Big Deal
The scale of the price difference is what makes this program significant, particularly for people on fixed incomes.
| Payment Route | Approximate Monthly Cost | Annual Cost |
|---|---|---|
| Medicare GLP-1 Bridge | $50 | $600 |
| Manufacturer self-pay (Wegovy) | $349-$399 | $4,188-$4,788 |
| Compounded telehealth program | $249-$399 | $2,988-$4,788 |
| Undiscounted retail list price | $1,000-$1,600 | $12,000-$19,200 |
For a Medicare beneficiary on a fixed income, the difference between $50 and $400 per month is frequently the difference between taking a medication and not taking it. Over the roughly 18-month program window, an eligible beneficiary would pay around $900 rather than $6,000 or more.
There is also a clinical argument specific to older adults. GLP-1 medications improve several conditions that are especially common in the Medicare population: type 2 diabetes, obstructive sleep apnea, osteoarthritis pain driven by joint loading, and cardiovascular risk. The population with the most to gain has, until now, had the least access.
Why "Outside Part D" Matters to Your Wallet
This detail gets glossed over in most coverage of the program, and it has real financial consequences.
GLP-1 drugs furnished under the Bridge are provided outside the Part D benefit. The program is separate from your regular Medicare Part D drug coverage. Practically, that means:
- Your $50 payments do not count toward your Part D deductible. If you have a deductible to satisfy for your other medications, Bridge spending will not chip away at it.
- They do not count toward your Part D out-of-pocket threshold. This is the more consequential point. Part D includes an annual out-of-pocket cap, after which your other drugs become much cheaper. Bridge spending does not move you toward that cap.
- Your plan's formulary rules may not apply in the usual way. The Bridge operates under its own structure rather than your plan's standard tiers.
- The $50 is a flat amount, not a percentage. It does not vary with the drug's list price, which is what makes it predictable and budgetable.
If you take several expensive medications, factor this in. Someone with high total drug spending who would otherwise reach their Part D out-of-pocket cap should understand that Bridge payments sit outside that calculation. This does not make the Bridge a bad deal - $50 a month is dramatically better than any alternative - but it does mean the savings do not compound with your other drug costs the way in-benefit spending would.
Your Part D plan's customer service line and the Medicare helpline can both walk you through how the Bridge interacts with your specific plan.
Who Is Eligible
The baseline requirement is straightforward: you must be a Medicare beneficiary with Part D prescription drug coverage. Beyond that, CMS specifies which beneficiaries and which medications qualify, and those determinations are made by Medicare.
Verify Your Eligibility Directly
We are deliberately not publishing a checklist of clinical criteria here. Eligibility rules for federal demonstration programs are specific, subject to change, and misreporting them can cost someone access or set up a false expectation.
Confirm your eligibility through official sources only: call 1-800-MEDICARE (1-800-633-4227), visit Medicare.gov, or ask your Part D plan directly. Your prescriber can also confirm whether your clinical situation fits the program's requirements.
What to Have Ready When You Call
- Your Medicare number and Part D plan information
- Your current height, weight, and BMI
- A list of weight-related conditions you have been diagnosed with - type 2 diabetes, sleep apnea, hypertension, cardiovascular disease, osteoarthritis
- Any GLP-1 medications you are currently taking or have taken previously
- Your prescriber's name and contact details
If you are already taking a GLP-1 for type 2 diabetes under existing Part D coverage, ask specifically how the Bridge interacts with your current arrangement - your situation may already be handled differently.
Which Medications Are Covered
CMS describes the program as covering certain GLP-1 medications. Reporting on the program indicates it allows Part D beneficiaries to access GLP-1 weight loss medications including Foundayo, Wegovy, and Zepbound - notably covering the newer oral option alongside the established injectables:
| Medication | Active Ingredient | Form |
|---|---|---|
| Wegovy | Semaglutide | Weekly injection |
| Ozempic | Semaglutide | Weekly injection |
| Zepbound | Tirzepatide | Weekly injection |
| Foundayo | Orforglipron | Daily oral tablet |
Confirm your specific drug before assuming coverage. The list of eligible medications is set by CMS and can be updated - other products such as the Wegovy pill and Wegovy HD may or may not be included at any given time, and dose-level restrictions may apply. Do not switch medications or make treatment decisions based on a coverage assumption. Ask Medicare or your Part D plan about the exact drug and dose you are prescribed.
One thing that is clear: the Bridge covers FDA-approved brand-name medications. Compounded semaglutide and tirzepatide from telehealth programs are not covered by Medicare under this or any other program, since compounded drugs are not FDA-approved products.
Timeline and What Happens in 2028
| Date | What Happens |
|---|---|
| Early 2026 | Reduced GLP-1 cash prices begin phasing in through direct-to-consumer channels |
| July 1, 2026 | Medicare GLP-1 Bridge begins - $50 monthly copay for eligible beneficiaries |
| December 31, 2027 | Program is currently scheduled to end |
| 2028 onward | Not yet determined - depends on program evaluation and any statutory changes |
The end date is the part worth planning around. Demonstration programs are evaluated on outcomes and cost, and they can be extended, expanded, modified, or allowed to expire. Nothing about the current structure guarantees continuation past 2027.
Plan for the possibility that coverage ends. Weight regain after stopping a GLP-1 is well documented across every drug in the class, so an abrupt end to affordable access is a real risk to manage rather than a hypothetical. Use the coverage window to build the habits that protect your results - protein intake, resistance training, sleep, and structured eating patterns - so you are not relying on the medication alone. Our guides on weight regain after stopping GLP-1 medications and preventing muscle loss are the two most important places to start.
How to Find Out If You Qualify
There is no third-party service that can enroll you, and you should be skeptical of anyone claiming otherwise. Work through official channels:
- Call 1-800-MEDICARE (1-800-633-4227). This is the authoritative source on your eligibility. TTY users can call 1-877-486-2048.
- Visit Medicare.gov. CMS publishes program materials on the Medicare GLP-1 Bridge, including a beneficiary-facing publication explaining how it works.
- Contact your Part D plan directly. Your plan can explain how the Bridge interacts with your specific coverage, and how it affects your deductible and out-of-pocket calculations.
- Talk to your prescriber. Your doctor can confirm whether your clinical circumstances meet the program's requirements and handle any documentation needed.
- Use your State Health Insurance Assistance Program (SHIP). Every state has one, and they provide free, unbiased Medicare counseling - particularly useful for navigating how a demonstration program affects your overall coverage.
Watch for scams. Any new Medicare program attracts fraudulent callers. Medicare will not call you unsolicited asking for your Medicare number, bank details, or payment to "enroll" you in the GLP-1 Bridge. Never give your Medicare number to an unsolicited caller. If someone contacts you claiming to sign you up, hang up and call 1-800-MEDICARE yourself.
If You Are Not Eligible
Not everyone who wants a GLP-1 will qualify for the Bridge, and many readers are not on Medicare at all. Here are the realistic alternatives, roughly in order of cost.
- Manufacturer self-pay programs. NovoCare offers Wegovy from $149/month at starting doses, $349/month at standard maintenance, and $399/month for Wegovy HD. LillyDirect offers Foundayo from $149/month. These require no insurance.
- Compounded semaglutide or tirzepatide. Physician-supervised telehealth programs typically run $249-$399/month with medication, consultation, and shipping bundled. See cheapest GLP-1 options.
- Commercial insurance appeals. If you have employer coverage that denied a weight loss medication, a documented appeal citing weight-related comorbidities succeeds more often than people expect.
- Manufacturer patient assistance programs. Both Novo Nordisk and Eli Lilly run assistance programs with income-based eligibility separate from their self-pay pricing.
For a full breakdown of low-cost routes, see our guides to the cheapest semaglutide and cheapest tirzepatide.
Not on Medicare? Compounded Semaglutide from $249/month
If the Bridge program is not an option, physician-supervised compounded semaglutide is the most affordable supervised route for most people. Coreage Rx includes the medical consultation, medication, shipping, and ongoing dose management in one flat monthly price - no insurance required.
Frequently Asked Questions
Is Medicare covering GLP-1 drugs for weight loss in 2026?
Yes, through the Medicare GLP-1 Bridge demonstration program, which began July 1, 2026. Eligible beneficiaries with Part D coverage can access certain GLP-1 medications for a $50 monthly copay. This is a time-limited demonstration currently scheduled to run through December 31, 2027, and the drugs are furnished outside the standard Part D benefit rather than through it.
How much will I pay for Ozempic or Wegovy under the Bridge?
Eligible beneficiaries pay a flat $50 copay for a monthly supply. This is a fixed amount rather than a percentage, so it does not vary with the drug's list price. Compare that to $349-$399 per month through manufacturer self-pay programs, or $1,000-$1,600 per month at undiscounted retail.
Does my $50 copay count toward my Part D out-of-pocket maximum?
No. GLP-1 drugs furnished under the Bridge are provided outside the Part D benefit, so those payments do not count toward your Part D deductible or your annual out-of-pocket threshold. If you take multiple expensive medications and expect to reach your Part D cap, it is worth understanding that Bridge spending sits outside that calculation.
How do I enroll in the Medicare GLP-1 Bridge?
Contact Medicare directly at 1-800-MEDICARE (1-800-633-4227), visit Medicare.gov, or ask your Part D plan. Your prescriber can confirm whether your clinical situation fits the program requirements. No third-party company can enroll you, and Medicare will never call you unsolicited asking for your Medicare number or payment to sign you up.
Which medications are included?
CMS describes the program as covering certain GLP-1 medications. Reporting indicates the program covers GLP-1 weight loss medications including Foundayo, Wegovy, and Zepbound, and Ozempic has featured in public discussion of the program. The eligible drug list is set by CMS and can be updated, so other products like the Wegovy pill or Wegovy HD may or may not be included at any given time. Confirm your specific medication and dose with Medicare or your plan before making treatment decisions.
Does the Bridge cover compounded semaglutide?
No. The Bridge covers FDA-approved brand-name medications. Compounded semaglutide and tirzepatide obtained through telehealth programs are not FDA-approved products and are not covered by Medicare under this or any other program. If you are currently using a compounded product and become eligible for the Bridge, the brand-name route will almost certainly be cheaper for you.
What happens when the program ends in December 2027?
That has not been determined. Demonstration programs are evaluated on outcomes and cost, and can be extended, expanded, modified, or allowed to expire. Because weight regain after stopping a GLP-1 is well documented, treat the coverage window as time to build habits that protect your results - protein intake, resistance training, sleep, and structured eating - rather than assuming indefinite access.
Why did Medicare not cover weight loss drugs before?
A longstanding statutory exclusion barred Medicare Part D from covering drugs used for weight loss, dating to a period when such drugs were viewed as cosmetic. It produced the odd result that semaglutide was coverable as Ozempic for type 2 diabetes but excluded as Wegovy for obesity. The Bridge provides access without waiting for that exclusion to be rewritten, which is exactly why the drugs are furnished outside the Part D benefit.
I have Medicare Advantage. Am I eligible?
The baseline requirement is Medicare with Part D prescription drug coverage, and many Medicare Advantage plans include Part D drug coverage. Because Medicare Advantage plans vary considerably in structure, confirm your specific situation with both your plan and 1-800-MEDICARE rather than assuming based on a general description.
I already take Ozempic for diabetes. Does this change anything for me?
Possibly, and it is worth asking about specifically. GLP-1 medications prescribed for type 2 diabetes were already coverable under Part D, so your existing arrangement may already be handled differently from the Bridge. Ask your Part D plan how the two interact for your particular prescription before changing anything about your current treatment.
Disclaimer
This article is for informational purposes only and does not constitute medical, legal, or insurance advice. It is not affiliated with, endorsed by, or produced by the Centers for Medicare & Medicaid Services or any government agency. Program details, eligibility criteria, covered medications, and dates reflect publicly available information at the time of writing and are subject to change. Always verify your eligibility and coverage directly with Medicare at 1-800-MEDICARE, at Medicare.gov, or with your Part D plan. GLP-1 medications are prescription drugs that should only be used under the supervision of a qualified healthcare provider. HealthyPound may receive compensation from affiliate partners mentioned in this article. See our affiliate disclosure and full medical disclaimer for more information.